Impax Laboratories Inc (IPXL)

[dangerx]

Look at spending on compounded drugs over the same period... at least there’s a logical reason for the price decline. Following the health care trends will give incredible insight into why they’re making the moves they are making. Amneal has vision to compete with Teva and Mylan IMO

[Tanis2476]

What carnage, from $51 to $10 in two years? That's an epic fail. What a train wreck.

[PhoenixwingzZ]

for all those longs holding that are depressed about the new low, I'm new to the board okay? and when I say that your times have come to profit, im like the black death bellringer screaming "bring out your dead". I'm not even invested one share deep, and idk if all longs heard about how Impax went public with offering an alternative EpiPen thats 6x cheaper than EpiPen itself? thats groundbreaking. really. The ask is two dollars over the real-time pps, though there's no possible way Impax will downtrend as a result of telling all allergics, "hey! 700$ EpiPen bogging you down? buy ours for $110." If the EpiPen market flocking to Impax doesnt make the share price go up in terms of product revenue, the good reviews about its' viability definitely will. I'm scrounging up every penny I got and I'm IN. Y'know how easy it was to find the index for Impax too? snap of the fingers. Something good is definitely about to happen with this lab.

[NathanH]

Back in at 14.38

[NathanH]

I got a few at 21.54

[Saremi777]

Reversal time I believe.

[masahirox]

Nice entry point

[T695]

Coup see a nice pop here

[stocktrademan]

$IPXL recent news/filings

bullish 41.70
hidden bullish divergence

## source: finance.yahoo.com

Tue, 10 Nov 2015 01:35:47 GMT ~ Biz Break: Yahoo hires expert to help with reorganization, report says


read full: http://www.mercurynews.com/60-second-business-break/ci_29094637/biz-break-yahoo-hires-expert-help-reorganization-report
*********************************************************

Mon, 09 Nov 2015 20:56:24 GMT ~ Edited Transcript of IPXL earnings conference call or presentation 9-Nov-15 1:30pm GMT


read full: http://finance.yahoo.com/news/edited-transcript-ipxl-earnings-conference-205624026.html
*********************************************************

Mon, 09 Nov 2015 17:58:53 GMT ~ Why Are These Four Stocks Gaining Ground on Monday?


read full: http://www.insidermonkey.com/blog/why-are-these-four-stocks-gaining-ground-on-monday-383126/
*********************************************************

Mon, 09 Nov 2015 13:27:52 GMT ~ IMPAX LABORATORIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, F


read full: http://biz.yahoo.com/e/151109/ipxl8-k.html
*********************************************************

Mon, 09 Nov 2015 12:16:08 GMT ~ Impax Reports Third Quarter 2015 Financial Results

[at noodls] - Impax Reports Third Quarter 2015 Financial Results

read full: http://www.noodls.com/view/7441FADDFAC56F386BCB58D85FDCB448A675DCA6
*********************************************************

$IPXL charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$IPXL company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/IPXL/company-info
Ticker: $IPXL
OTC Market Place: Not Available
CIK code: 0001003642
Company name: Impax Laboratories, Inc.
Company website: http://www.impaxlabs.com
Incorporated In: DE, USA

$IPXL share structure

## source: otcmarkets.com

Market Value: $3,015,104,364 a/o Nov 13, 2015
Shares Outstanding: 72,304,661 a/o Aug 03, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01

$IPXL extra dd links

Company name: Impax Laboratories, Inc.
Company website: http://www.impaxlabs.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=IPXL+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=IPXL+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=IPXL+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/IPXL/news - http://finance.yahoo.com/q/h?s=IPXL+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/IPXL/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/IPXL/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=IPXL+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/IPXL
DTCC (dtcc.com): http://search2.dtcc.com/?q=Impax+Laboratories%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Impax+Laboratories%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Impax+Laboratories%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.impaxlabs.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.impaxlabs.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.impaxlabs.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/IPXL
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001003642&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/IPXL/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/IPXL/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=IPXL&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=IPXL
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/IPXL/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=IPXL+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=IPXL+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=IPXL
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=IPXL
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=IPXL+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/IPXL/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=IPXL+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/IPXL.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=IPXL
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/IPXL/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/IPXL
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/IPXL
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/IPXL:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=IPXL
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=IPXL



$IPXL DD Notes ~ http://www.ddnotesmaker.com/IPXL

[stocktrademan]

$IPXL recent news/filings

bullish

## source: finance.yahoo.com

Fri, 29 May 2015 15:20:25 GMT ~ Who's The Next Big Pharma Acquisition?


read full: http://finance.yahoo.com/news/whos-next-big-pharma-acquisition-152025993.html
*********************************************************

Fri, 22 May 2015 20:24:24 GMT ~ IMPAX LABORATORIES INC Files SEC form 8-K/A, Submission of Matters to a Vote of Security Holders


read full: http://biz.yahoo.com/e/150522/ipxl8-k_a.html
*********************************************************

Wed, 20 May 2015 17:04:27 GMT ~ IMPAX LABORATORIES INC Financials


read full: http://finance.yahoo.com/q/is?s=ipxl
*********************************************************

Fri, 15 May 2015 20:42:16 GMT ~ IMPAX LABORATORIES INC Files SEC form 8-K/A, Financial Statements and Exhibits


read full: http://biz.yahoo.com/e/150515/ipxl8-k_a.html
*********************************************************

Thu, 14 May 2015 20:26:30 GMT ~ Top New Picks of Healthcare Fund Blue Jay Capital: Endo International plc (ENDP), Alkermes Plc (ALKS), Akorn Inc. (AKRX)


read full: http://www.insidermonkey.com/blog/top-new-picks-of-healthcare-fund-blue-jay-capital-endo-international-plc-endp-alkermes-plc-alks-akorn-inc-akrx-347220/
*********************************************************

$IPXL charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$IPXL company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/IPXL/company-info
Ticker: $IPXL
OTC Market Place: Not Available
CIK code: 0001003642
Company name: Impax Laboratories, Inc.
Company website: http://www.impaxlabs.com
Incorporated In: DE, USA


$IPXL share structure

## source: otcmarkets.com

Market Value: $3,370,720,563 a/o May 29, 2015
Shares Outstanding: 71,702,203 a/o May 01, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01

$IPXL extra dd links

Company name: Impax Laboratories, Inc.
Company website: http://www.impaxlabs.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=IPXL+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=IPXL+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=IPXL+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/IPXL/news - http://finance.yahoo.com/q/h?s=IPXL+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/IPXL/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/IPXL/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=IPXL+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/IPXL
DTCC (dtcc.com): http://search2.dtcc.com/?q=Impax+Laboratories%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Impax+Laboratories%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Impax+Laboratories%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.impaxlabs.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.impaxlabs.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.impaxlabs.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/IPXL
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001003642&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/IPXL/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/IPXL/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=IPXL&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=IPXL
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/IPXL/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=IPXL+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=IPXL+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=IPXL
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=IPXL
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=IPXL+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/IPXL/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=IPXL+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/IPXL.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=IPXL
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/IPXL/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/IPXL
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/IPXL
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/IPXL:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=IPXL
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=IPXL



$IPXL DD Notes ~ http://www.ddnotesmaker.com/IPXL

[MONEYMADE]

Ahhhhh yeeee...Yup you are right.

[Mr Clutch]

I tried posting earlier today and it said a premium membership needed. I appreciate the invite!

[MONEYMADE]

FEEL FREE TO STOP BY MY BOARD AND KEEP US ALL INFORMED OF YOUR PROGRESS.
YOU MIGHT BE ABLE TO HELP SOMEONE ELSE FACING SIMILAR PERILS AND CAN BE A LEADER.

HANG IN THERE BUD...THAT'S WHY I'M HERE ON IPXL THEY ARE DOING SOME GOOD THINGS IN THIS AREA.

[Mr Clutch]

Appreciate ya...my family and I are still digesting it. But, got to keep living life. I have a the good Lord, my beautiful wife and my 2 beautiful little kids. Take care.

[MONEYMADE]

Really,,,well lobster21_78 You'll make it...I wish you a speedy recovery.

[OB_WEALTH_INC]

NO thanks...Not interested ....IPXL

[Mr Clutch]

Interesting...I was just diagnosed with Parkinson's. Thanks man!

[MONEYMADE]

Anyone buying...FDA approval! Parkinsons....HUGE

[stocktrademan]

$IPXL DD Notes ~ http://www.ddnotesmaker.com/IPXL

bullish

$IPXL recent news/filings

## source: finance.yahoo.com

Thu, 04 Dec 2014 03:21:04 GMT ~ Impax Laboratories, Inc. -- Moody's Assigns B1 CFR to Impax; Stable Outlook


read full: http://www.moodys.com/page/viewresearchdoc.aspx?docid=PR_314214&WT.mc_id=AM~WWFob29fRmluYW5jZTQyX1NCX1JhdGluZyBOZXdzX0FsbF9Fbmc=~20141203_PR_314214
*********************************************************

Tue, 02 Dec 2014 14:03:25 GMT ~ IMPAX LABORATORIES INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits


read full: http://biz.yahoo.com/e/141202/ipxl8-k.html
*********************************************************

Fri, 28 Nov 2014 10:40:47 GMT ~ Is Impax Laboratories (IPXL) Stock a Solid Choice Right Now?


read full: http://finance.yahoo.com/news/impax-laboratories-ipxl-stock-solid-104047428.html
*********************************************************

Wed, 19 Nov 2014 12:31:19 GMT ~ Corium International (CORI) Jumps: Stock Moves 14.3% Higher


read full: http://finance.yahoo.com/news/corium-international-cori-jumps-stock-123119604.html
*********************************************************

Fri, 14 Nov 2014 18:04:33 GMT ~ IMPAX LABORATORIES INC Financials


read full: http://finance.yahoo.com/q/is?s=ipxl
*********************************************************


$IPXL charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$IPXL company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/IPXL/company-info
Ticker: $IPXL
OTC Market Place: Not Available
CIK code: 0001003642
Company name: Impax Laboratories, Inc.
Company website: http://www.impaxlabs.com
Incorporated In: DE, USA


$IPXL share structure

## source: otcmarkets.com

Market Value: $2,279,237,820 a/o Dec 26, 2014
Shares Outstanding: 71,248,447 a/o Oct 31, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
$IPXL extra dd links

Company name: Impax Laboratories, Inc.
Company website: http://www.impaxlabs.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=IPXL+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=IPXL+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=IPXL+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/IPXL/news - http://finance.yahoo.com/q/h?s=IPXL+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/IPXL/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/IPXL/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=IPXL+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/IPXL
DTCC (dtcc.com): http://search2.dtcc.com/?q=Impax+Laboratories%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Impax+Laboratories%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Impax+Laboratories%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.impaxlabs.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.impaxlabs.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.impaxlabs.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/IPXL
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001003642&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/IPXL/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/IPXL/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=IPXL&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=IPXL
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/IPXL/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=IPXL+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=IPXL+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=IPXL
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=IPXL
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=IPXL+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/IPXL/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=IPXL+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/IPXL.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=IPXL
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/IPXL/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/IPXL/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/IPXL
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/IPXL
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/IPXL:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=IPXL
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=IPXL



$IPXL DD Notes ~ http://www.ddnotesmaker.com/IPXL

[ProfitScout]

Impax and DURECT Sign a $63 Million Agreement to Develop and Commercialize DURECT's ELADUR(R) Pain Patch

HAYWARD, Calif. & CUPERTINO, Calif., Jan 07, 2014 (BUSINESS WIRE) -- Impax Laboratories, Inc.(NASDAQ:IPXL) and DURECT Corporation (Nasdaq:DRRX) announced today that they have entered into an agreement granting Impax the exclusive worldwide rights to develop and commercialize ELADUR(R), DURECT's investigational transdermal bupivacaine patch for the treatment of pain associated with post-herpetic neuralgia (PHN).

Under the terms of the agreement, Impax will pay DURECT an upfront fee of $2 million, with possible additional payments of up to $61 million upon the achievement of predefined development and commercialization milestones. If ELADUR is commercialized, DURECT would also receive a tiered royalty on product sales. Impax will control and fund the development program.

"We're pleased to be moving ELADUR back into development through this collaboration with Impax," stated James E. Brown, president and CEO of DURECT. "Existing patches used to treat PHN pain are limited by their 12 hour duration, followed by a rest period in which the patient is not to wear a patch for 12 hours. Episodes of break-through pain are frequently reported to occur during rest periods for existing patches. We share a vision with Impax to develop a patch that has the potential to reduce these episodes of break-through pain."

Michael Nestor, president of Impax Pharmaceuticals added, "This agreement is another example of our commitment to building a strong brand pipeline through internal R&D and external business development. We are excited to collaborate with DURECT as this product could, if approved, fit well with the capabilities of our neurology focused specialty sales force."

ELADUR is an investigational transdermal drug patch intended to deliver bupivacaine for up to three days from a single application. DURECT has previously announced positive results for ELADUR from a 60 patient Phase IIa clinical trial of patients suffering from PHN.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. (Impax) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams and ointments. For more information, please visit the Company's Web site at: http://www.impaxlabs.com.

About DURECT Corporation

DURECT is a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY(R), POSIDUR(TM), ELADUR(R), and TRANSDUR(R)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit http://www.durect.com.

Impax Laboratories Forward-Looking Statement

To the extent any statements made in this news release contain information that is not historical, these statements are forward-looking in nature and express the beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the effect of current economic conditions on the Company's industry, business, financial position and results of operations, fluctuations in revenues and operating income, the Company's ability to promptly correct the issues raised in the warning letter and Form 483 observations received from the FDA, the Company's ability to successfully develop and commercialize pharmaceutical products in a timely manner, reductions or loss of business with any significant customer, the impact of consolidation of the Company's customer base, the impact of competition, the Company's ability to sustain profitability and positive cash flows, any delays or unanticipated expenses in connection with the operation of the Company's Taiwan facility, the effect of foreign economic, political, legal and other risks on the Company's operations abroad, the uncertainty of patent litigation, the increased government scrutiny on the Company's agreements with brand pharmaceutical companies, consumer acceptance and demand for new pharmaceutical products, the impact of market perceptions of the Company and the safety and quality of the Company's products, the difficulty of predicting FDA filings and approvals, the Company's ability to achieve returns on its investments in research and development activities, the Company's inexperience in conducting clinical trials and submitting new drug applications, the Company's ability to successfully conduct clinical trials, the Company's reliance on third parties to conduct clinical trials and testing, impact of illegal distribution and sale by third parties of counterfeits or stolen products, the availability of raw materials and impact of interruptions in the Company's supply chain, the use of controlled substances in the Company's products, disruptions or failures in the Company's information technology systems and network infrastructure, the Company's reliance on alliance and collaboration agreements, the Company's dependence on certain employees, the Company's ability to comply with legal and regulatory requirements governing the healthcare industry, the regulatory environment, the Company's ability to protect its intellectual property, exposure to product liability claims, changes in tax regulations, the Company's ability to manage growth, including through potential acquisitions, the restrictions imposed by the Company's credit facility, uncertainties involved in the preparation of the Company's financial statements, the Company's ability to maintain an effective system of internal control over financial reporting, the effect of terrorist attacks on the Company's business, the location of the Company's manufacturing and research and development facilities near earthquake fault lines and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission. Forward-looking statements speak only as to the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, regardless of whether new information becomes available, future developments occur or otherwise.

DURECT Forward-Looking Statement

The statements in this press release regarding ELADUR, its anticipated attributes, potential uses and commercial potential, and the milestone and royalty payments that may be potentially paid to DURECT under DURECT's license agreement with Impax are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risk that ELADUR may not receive regulatory approval, Impax's ability to design, enroll, conduct and complete clinical trials to support regulatory approval, and DURECT and Impax's ability to complete the design, development, and manufacturing process development of ELADUR, Impax's ability to manufacture and commercialize ELADUR, marketplace acceptance of the product candidate and the risk that Impax may terminate the agreement under conditions specified in the agreement. Further information regarding these and other risks is included in DURECT's Form 10-Q dated November 5, 2013 filed with the Securities and Exchange Commission under the heading "Risk Factors."

NOTE: ORADUR(R), POSIDUR(TM), SABER(R), TRANSDUR(R), and ELADUR(R) are trademarks of DURECT Corporation. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

http://cts.businesswire.com/ct/CT?id=bwnews&sty=20140107005821r1&sid=cmtx6&distro=nx

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140107005821/en/

SOURCE: Impax Laboratories, Inc.

CONTACT:
Impax Laboratories, Inc. Mark Donohue, 215-558-4526 Vice President Investor Relations and Corporate Communications or DURECT Corporation Matthew J. Hogan, 408-777-4936 Chief Financial Officer

Copyright Business Wire 2014

[SatComSoldier]

I'm in at 19.84.

[Shark Attack]

This is going to 27.25 pending approval

[mlkrborn]

Impax Labs enters into development, manufacturing and commercialization agreement with Perrigo (PRGO); terms not disclosed (IPXL) 20.01 : IPXL announced that it will collaborate with Perrigo (PRGO) on the development, manufacturing and commercialization of an extended topical generic drug product with first to market potential. The product and terms of the agreement were not disclosed.

[boo boo]

Price acceleration into FDA determination date.

[boo boo]

Isn't there some kind of FDA bullhockeypuck announcement on the 10th?

[Penny Roger$]

~ Tuesday! $IPXL ~ Q1 Earnings posted, pending or coming soon! In Charts and Links Below!

~ $IPXL ~ Earnings expected on Tuesday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=IPXL&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=IPXL&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=IPXL
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=IPXL#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=IPXL+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=IPXL
Finviz: http://finviz.com/quote.ashx?t=IPXL
~ BusyStock: http://busystock.com/i.php?s=IPXL&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=IPXL >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

[Penny Roger$]

<<< $IPXL Links! >>> ~ MAC's Quick DD Links without the charts.



Open these links (or the ones you desire) in background tabs
http://help.opera.com/Linux/9.52/en/keyboard.html
http://lifehacker.com/263940/force-links-to-open-in-the-background


PennyStockTweets ~ http://www.pennystocktweets.com/stocks/profile/IPXL


OTC Markets Company Info ~ http://www.otcmarkets.com/stock/IPXL/company-info
OTC Markets Charts ~ http://www.otcmarkets.com/stock/IPXL/chart
OTC Markets Quote ~ http://www.otcmarkets.com/stock/IPXL/quote
OTC Markets News ~ http://www.otcmarkets.com/stock/IPXL/news
OTC Markets Financials ~ http://www.otcmarkets.com/stock/IPXL/financials
OTC Markets Short Sales ~ http://www.otcmarkets.com/stock/IPXL/short-sales
OTC Markets Insider Disclosure ~ http://www.otcmarkets.com/stock/IPXL/insider-transactions
OTC Markets Research Reports ~ http://www.otcmarkets.com/stock/IPXL/research


Google Finance Summary ~ http://www.google.com/finance?q=IPXL
Google Finance News ~ http://www.google.com/finance/company_news?q=IPXL
Google Finance Option chain ~ http://www.google.com/finance/option_chain?q=IPXL
Google Finance Financials ~ http://www.google.com/finance?q=IPXL&fstype=ii#
Google Finance Historical prices Daily ~ http://www.google.com/finance/historical?q=IPXL
Google Finance Historical prices Weekly ~ http://www.google.com/finance/historical?q=IPXL&histperiod=weekly#


Y! < Company >
Y! Profile ~ http://finance.yahoo.com/q/pr?s=IPXL+Profile
Y! Key Stat's ~ http://finance.yahoo.com/q/ks?s=IPXL+Key+Statistics
Y! Headlines ~ http://finance.yahoo.com/q/h?s=IPXL+Headlines
Y! Summary ~ http://finance.yahoo.com/q?s=IPXL
Y! Historical Prices ~ http://finance.yahoo.com/q/hp?s=IPXL+Historical+Prices
Y! Order Book ~ http://finance.yahoo.com/q/ecn?s=IPXL+Order+Book
Y! Message Boards ~ http://messages.finance.yahoo.com/mb/IPXL
Y! Market Pulse ~ http://finance.yahoo.com/marketpulse/IPXL
Y! Technical Analysis ~ http://finance.yahoo.com/q/ta?s=IPXL+Basic+Tech.+Analysis
Y! < Analyst Coverage >
Y! Analyst Opinion ~ http://finance.yahoo.com/q/ao?s=IPXL+Analyst+Opinion
Y! Analyst Estimates ~ http://finance.yahoo.com/q/ae?s=IPXL+Analyst+Estimates
Y! Research Reports ~ http://finance.yahoo.com/q/rr?s=IPXL+Research+Reports
Y! Star Analysts ~ http://finance.yahoo.com/q/sa?s=IPXL+Star+Analysts
Y! < Ownership >
Y! Major Holders ~ http://finance.yahoo.com/q/mh?s=IPXL+Major+Holders
Y! Insider Transactions ~ http://finance.yahoo.com/q/it?s=IPXL+Insider+Transactions
Y! Insider Roster ~ http://finance.yahoo.com/q/ir?s=IPXL+Insider+Roster
Y! < Financials >
Y! Income Statement ~ http://finance.yahoo.com/q/is?s=IPXL+Income+Statement&annual
Y! Balance Sheet ~ http://finance.yahoo.com/q/bs?s=IPXL+Balance+Sheet&annual
Y! Cash Flow ~ http://finance.yahoo.com/q/cf?s=IPXL+Cash+Flow&annual


FINVIZ ~ http://finviz.com/quote.ashx?t=IPXL&ty=c&ta=0&p=d


Investorshub Trades ~ http://ih.advfn.com/p.php?pid=trades&symbol=IPXL
Investorshub Board Search ~ http://investorshub.advfn.com/boards/getboards.aspx?searchstr=IPXL
Investorshub PostStream ~ http://investorshub.advfn.com/boards/poststream.aspx?ticker=IPXL
Investorshub Messages ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=IPXL
Investorshub Videos ~ http://ih.advfn.com/p.php?pid=ihvse&ihvqu=IPXL
Investorshub News ~ http://ih.advfn.com/p.php?pid=news&btn=s_ok&ctl00%24sb3%24tbq1=Get+Quote&as_values_IH=&ctl00%24sb3%24stb1=Search+iHub&symbol=IPXL&s_ok=OK&from_month=3&from_day=15&from_year=2012&order=desc&selsrc%5B%5D=prnca&selsrc%5B%5D=prnus&selsrc%5B%5D=zacks&selsrc%5B%5D=money2&selsrc%5B%5D=djn&selsrc%5B%5D=bw&selsrc%5B%5D=globe&selsrc%5B%5D=edgar&selsrc%5B%5D=mwus&force=1&last_ts=1331855999&p_n=1&p_count=&p_ts=1331794260


CandlestickChart ~ http://www.candlestickchart.com/cgi/chart.cgi?symbol=IPXL&exchange=US


Barchart Quote ~ http://barchart.com/quotes/stocks/IPXL?
Barchart Detailed Quote ~ http://barchart.com/detailedquote/stocks/IPXL
Barchart Options Quotes ~ http://barchart.com/options/stocks/IPXL
Barchart Technical Chart ~ http://barchart.com/charts/stocks/IPXL&style=technical
Barchart Interactive Chart ~ http://barchart.com/charts/stocks/IPXL&style=interactive
Barchart Technical Analysis ~ http://barchart.com/technicals/stocks/IPXL
Barchart Trader's Cheat Sheet ~ http://barchart.com/cheatsheet.php?sym=IPXL
Barchart Barchart Opinion ~ http://barchart.com/opinions/stocks/IPXL
Barchart Snapshot Opinion ~ http://barchart.com/snapopinion/stocks/IPXL
Barchart News Headlines ~ http://barchart.com/news/stocks/IPXL
Barchart Profile ~ http://barchart.com/profile//IPXL
Barchart Key Statistics ~ http://barchart.com/profile.php?sym=IPXL&view=key_statistics


OTC: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=IPXL&MarketTicker=OTC&TYP=S
NASDAQ: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=IPXL&MarketTicker=NASD&TYP=S
NYSE: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=IPXL&MarketTicker=NYSE&Typ=S


Marketwatch Profile ~ http://www.marketwatch.com/investing/stock/IPXL/profile
Marketwatch Analyst Estimates ~ http://www.marketwatch.com/investing/stock/IPXL/analystestimates
Marketwatch Historical Quotes ~ http://www.marketwatch.com/investing/stock/IPXL/historical
Marketwatch Financials ~ http://www.marketwatch.com/investing/stock/IPXL/financials
Marketwatch Overview ~ http://www.marketwatch.com/investing/stock/IPXL
Marketwatch SEC Filings ~ http://www.marketwatch.com/investing/stock/IPXL/secfilings
Marketwatch Picks ~ http://www.marketwatch.com/investing/stock/IPXL/picks
Marketwatch Hulbert ~ http://www.marketwatch.com/investing/stock/IPXL/hulbert
Marketwatch Insider Actions ~ http://www.marketwatch.com/investing/stock/IPXL/insideractions
Marketwatch Options ~ http://www.marketwatch.com/investing/stock/IPXL/options
Marketwatch Charts ~ http://www.marketwatch.com/investing/stock/IPXL/charts
Marketwatch News ~ http://bigcharts.marketwatch.com/news/symbolsearch/symbolnews.asp?news=markadv&symb=IPXL&sid=1795093&framed=False


The Lion ~ http://thelion.com/bin/aio_msg.cgi?cmd=search&msg=&si=1&tw=1&tt=1&rb=1&ih=1&fo=1&iv=1&yf=1&sa=1&fb=1&gg=1&symbol=IPXL


Search NYSE ~ http://www.nyse.com/about/listed/lcddata.html?ticker=IPXL


StockTA ~ http://www.stockta.com/cgi-bin/analysis.pl?symb=IPXL&num1=567&cobrand=&mode=stock


StockHouse ~ http://www.stockhouse.com/financialtools/sn_overview.aspx?qm_symbol=IPXL
StockHouse Delayed LII ~ http://www.stockhouse.com/financialtools/sn_level2.aspx?qm_page=46140&qm_symbol=IPXL


AlphaTrade ~ http://tools.alphatrade.com/index.php?t1=mc_quote_module&t2=mc_quote_module2&t3=historical&template=historical2html&sym=IPXL&client_id=2740&a_width=680&a_height=1000&language=english&showVol=1&chtype=8


Reuters ~ http://www.reuters.com/finance/stocks/companyOfficers?symbol=IPXL.PK&WTmodLOC=C4-Officers-5


StockWatch ~ http://www.stockwatch.com/Quote/Detail.aspx?symbol=IPXL®ion=U


Search NASDAQ ~ http://www.nasdaq.com/symbol/IPXL
NASDAQ Divy History ~ http://www.nasdaq.com/symbol/IPXL/dividend-history
NASDAQ Short Interest ~ http://www.nasdaq.com/symbol/IPXL/short-interest
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/IPXL/institutional-holdings
NASDAQ FlashQuotes ~ http://www.nasdaq.com/aspx/flashquotes.aspx?symbol=IPXL&selected=IPXL
NASDAQ InfoQuotes ~ http://www.nasdaq.com/aspx/infoquotes.aspx?symbol=IPXL&selected=IPXL
NASDAQ After Hours Quote ~ http://www.nasdaq.com/symbol/IPXL/after-hours
NASDAQ Pre-Market Quote ~ http://www.nasdaq.com/symbol/IPXL/premarket
NASDAQ Historical Quote ~ http://www.nasdaq.com/symbol/IPXL/historical
NASDAQ Option Chain ~ http://www.nasdaq.com/symbol/IPXL/option-chain
NASDAQ Company Headlines ~ http://www.nasdaq.com/symbol/IPXL/news-headlines
NASDAQ Press Releases ~ http://www.nasdaq.com/symbol/IPXL/news-headlines
NASDAQ Sentiment ~ http://www.nasdaq.com/symbol/IPXL/sentiment
NASDAQ Analyst Summary ~ http://www.nasdaq.com/symbol/IPXL/analyst-research
NASDAQ Guru Analysis~ http://www.nasdaq.com/symbol/IPXL/guru-analysis
NASDAQ Stock Report ~ http://www.nasdaq.com/symbol/IPXL/stock-report
NASDAQ Competitors ~ http://www.nasdaq.com/symbol/IPXL/competitors
NASDAQ Stock Consultant ~ http://www.nasdaq.com/symbol/IPXL/stock-consultant
NASDAQ Stock Comparison ~ http://www.nasdaq.com/symbol/IPXL/stock-comparison
NASDAQ Call Transcripts ~ http://www.nasdaq.com/symbol/IPXL/call-transcripts
NASDAQ Annual Reports ~ http://www.nasdaq.com/aspx/annualreport.aspx?symbol=IPXL&selected=IPXL
NASDAQ Financials ~ http://www.nasdaq.com/symbol/IPXL/financials
NASDAQ Revenue & Earnings Per Share (EPS) ~ http://www.nasdaq.com/symbol/IPXL/revenue-eps
NASDAQ SEC Filings ~ http://www.nasdaq.com/symbol/IPXL/sec-filings
NASDAQ Ownership Summary ~ http://www.nasdaq.com/symbol/IPXL/ownership-summary
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/IPXL/institutional-holdings
NASDAQ (SEC Form 4) ~
--------- All Trades ~ http://www.nasdaq.com/symbol/IPXL/insider-trades
--------- Buys ~ http://www.nasdaq.com/symbol/IPXL/insider-trades/buys
--------- Sells ~ http://www.nasdaq.com/symbol/IPXL/insider-trades/sells


The Motley Fool ~ http://caps.fool.com/Ticker/IPXL.aspx
The Motley Fool Earnings/Growth ~ http://caps.fool.com/Ticker/IPXL/EarningsGrowthRates.aspx?source=itxsittst0000001
The Motley Fool Ratios ~ http://caps.fool.com/Ticker/IPXL/Ratios.aspx?source=itxsittst0000001
The Motley Fool Stats ~ http://caps.fool.com/Ticker/IPXL/Stats.aspx?source=icasittab0000006
The Motley Fool Historical ~ http://caps.fool.com/Ticker/IPXL/Historical.aspx?source=icasittab0000004
The Motley Fool Scorecard ~ http://caps.fool.com/Ticker/IPXL/Scorecard.aspx?source=icasittab0000003
The Motley Fool Statements ~ http://caps.fool.com/Ticker/IPXL/Statements.aspx?source=icasittab0000009


MSN Money ~ http://investing.money.msn.com/investments/stock-ratings?symbol=IPXL


YCharts ~ http://ycharts.com/companies/IPXL
YCharts Performance ~ http://ycharts.com/companies/IPXL/performance
YCharts Dashboard ~ http://ycharts.com/companies/IPXL/dashboard


InsideStocks Opinion ~ http://www.insidestocks.com/texpert.asp?sym=IPXL&code=XDAILY
InsideStocks Profile ~ http://www.insidestocks.com/profile.asp?sym=IPXL&code=XDAILY
InsideStocks Quote ~ http://www.insidestocks.com/quote.asp?sym=IPXL&code=XDAILY
InsideStocks Projection ~ http://charts3.barchart.com/procal.asp?sym=IPXL


Zacks Quote ~ http://www.zacks.com/stock/quote/IPXL
Zacks Estimates ~ http://www.zacks.com/research/report.php?type=estimates&t=IPXL
Zacks Company Reports ~ http://www.zacks.com/research/report.php?type=report&t=IPXL


Knobias ~ http://knobias.10kwizard.com/files.php?sym=IPXL


StockScores ~ http://www.stockscores.com/quickreport.asp?ticker=IPXL


Trade-Ideas ~ http://www.trade-ideas.com/StockInfo/IPXL/HOT_TOPIC.html


Morningstar ~ http://performance.morningstar.com/stock/performance-return.action?region=USA&t=IPXL&culture=en-US
Morningstar Shareholders ~ http://investors.morningstar.com/ownership/shareholders-overview.html?t=IPXL®ion=USA&culture=en-us
Morningstar Transcripts~ http://www.morningstar.com/earnings/NoTranscript.aspx?t=IPXL®ion=USA
Morningstar Key Ratios ~ http://financials.morningstar.com/ratios/r.html?t=IPXL®ion=USA&culture=en-US
Morningstar Executive Compensation ~ http://insiders.morningstar.com/trading/executive-compensation.action?t=IPXL®ion=USA&culture=en-us
Morningstar Valuation ~ http://financials.morningstar.com/valuation/price-ratio.html?t=IPXL®ion=USA&culture=en-us


CCBN (Thompson Reuters) ~ http://ccbn.aol.com/company.asp?client=aol&ticker=IPXL


TradingMarkets ~ http://pr.tradingmarkets.com/?lid=leftPRbox&sym=IPXL


OTCBB ~ http://www.otcbb.com/asp/SiteSearch.asp?Criteria=IPXL&searcharea=e&image1.x=0&image1.y=0


Insidercow ~ http://www.insidercow.com/history/company.jsp?company=IPXL&B1=Search%21


Forbes News ~ http://search.forbes.com/search/find?tab=searchtabgeneraldark&MT=IPXL
Forbes Press Releases ~ http://search.forbes.com/search/find?&start=1&tab=searchtabgeneraldark&MT=IPXL&pub=businesswire,prnewswire&searchResults=pressRelease&tag=pr&premium=on
Forbes Web ~ http://search.forbes.com/search/web?MT=UNGS&start=1&max=10&searchResults=web&tag=web&sort=null


YouTube Symbol Search ~ http://www.youtube.com/results?search_query=IPXL


Buy-Ins ~ http://www.buyins.net/tools/symbol_stats.php?sym=IPXL


Quotemedia ~ http://www.quotemedia.com/results.php?qm_page=47556&qm_symbol=IPXL


Earnings Whispers ~ http://www.earningswhispers.com/stocks.asp?symbol=IPXL

Bloomberg Snapshot ~ http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=IPXL
Bloomberg People ~ http://investing.businessweek.com/research/stocks/people/people.asp?ticker=IPXL

Financial Times ~ http://markets.ft.com/Research/Markets/Tearsheets/Summary?s=IPXL

Investorpoint ~ http://www.investorpoint.com/ enter "IPXL" and click search.

Hotstocked ~ http://www.hotstocked.com/ enter "IPXL" and click search.

Raging Bull ~ http://ragingbull.quote.com/mboard/boards.cgi?board=IPXL

Hoovers ~ http://www.hoovers.com/search/company-search-results/100003765-1.html?type=company&term=IPXL

DD Machine ~ http://www.ddmachine.com/default.asp?m=stocktool_frame.asp?symbol=IPXL

SEC Form 4 ~ http://www.secform4.com/insider/showhistory.php?cik=IPXL

OTCBB Pulse ~ http://www.otcbbpulse.com/cgi-bin/pulsequote.cgi?symbol=IPXL

Failures To Deliver ~ http://failurestodeliver.com/default2.aspx enter "IPXL" and click search.

http://www.coordinatedlegal.com/SecretaryOfState.html

http://regsho.finra.org/regsho-Index.html

http://www.shortsqueeze.com/?symbol=IPXL&submit=Short+Quote%99



DTCC (PENSON/TDA) Check - (otc and pinks) - Note ~ I did not check for this chart blast. However, I try and help you to do so with the following links.
IHUB DTCC BOARD SEARCH #1 http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=IPXL
IHUB DTCC BOARD SEARCH #2: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=14482&srchyr=2011&SearchStr=IPXL
Check those searches for recent IPXL mentions. If IPXL is showing up on older posts and not on new posts found in link below, The DTCC issues may have been addressed and fixed. Always call the broker if your security turns up on any DTCC/PENSON list.
http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=Complete+list
For a complete list see the pinned threads at the top here ---> http://tinyurl.com/TWO-OLD-FARTS



MACDlinks

[Penny Roger$]

~ Tuesday! $IPXL ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $IPXL ~ Earnings expected on Tuesday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=IPXL&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=IPXL&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=IPXL
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=IPXL#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=IPXL+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=IPXL
Finviz: http://finviz.com/quote.ashx?t=IPXL
~ BusyStock: http://busystock.com/i.php?s=IPXL&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=IPXL >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

[mlkrborn]

Impax Labs Submits New Drug Application for IPX066 in Parkinson's Disease (IPXL) 19.89 : Impax Pharmaceuticals, the branded products division of IPXL announced the submission of Impax's New Drug Application for IPX066 to the U.S. Food and Drug Administration for the treatment of idiopathic Parkinson's disease. IPX066 is a patented extended release capsule formulation of carbidopa-levodopa. IPX066 is being developed in collaboration with GlaxoSmithKline (GSK) for territories outside the U.S. and Taiwan.

[K from Cal]

This has been a nice run lately. Just sold my Calls for a 95% gain. Rock N Roll.

[MrBruce]

Impax Laboratories Enters into Commercialization Agreement with Banner Pharmacaps

HAYWARD, Calif. & HIGH POINT, N.C., Apr 08, 2011 (BUSINESS WIRE) --

Impax Laboratories, Inc.(NASDAQ: IPXL) today announced that it will collaborate with Banner Pharmacaps Inc. with respect to the supply and commercialization of two softgel capsule products. The products and terms of the agreement were not disclosed.

Larry Hsu, Ph.D., president and CEO of Impax Laboratories, said: "We are excited to collaborate with Banner, a global leader in developing and manufacturing softgel products. In less than a year, we have entered into four distinct partnerships for alternate dosage form products as we continue to execute our strategy of diversifying our product base. Our business development activities will continue to focus on delivering growth from high-value products, technologies, and businesses in complementary dosage forms."

Roger E. Gordon, Ph.D., president and CEO of Banner Pharmacaps Inc., added: "We are delighted to be joining forces with Impax, a specialty pharmaceutical company whose vision and goals so closely mirror those of Banner. They join our expanding list of partners who look to Banner to provide expertise in the development of gelatin-based drug delivery systems and unique technology platforms."

[MrBruce]

Impax Laboratories Confirms Patent Challenge Relating to DEXILANT(R) Delayed-ReleaseCapsules, 30 mg and 60 mg

HAYWARD, Calif., Apr 04, 2011 (BUSINESS WIRE) --

Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that it has initiated a challenge of patents listed by Takeda Pharmaceutical Company, Ltd. in connection with DEXILANT(R) (dexlansoprazole) delayed-release capsules, 30 mg and 60 mg.

Impax filed its Abbreviated New Drug Application (ANDA) containing a paragraph IV certification for a generic version of DEXILANT(R) with the U.S. Food & Drug Administration (FDA). Following receipt of the notice from the FDA that Impax's ANDA had been accepted for filing, Impax notified the New Drug Application holder and patent owner of its paragraph IV certification.

On April 1, Takeda Pharmaceuticals Co. LTD, Takeda Pharmaceuticals North America Inc., Takeda Pharmaceuticals LLC and Takeda Pharmaceuticals America Inc. filed suit for patent infringement against Impax in Northern District of California. This action formally initiates the patent challenge process under the Hatch-Waxman Act. Based on the filing date of the ANDA, the Company believes that it is the first to file an ANDA with a paragraph IV certification on the 30 mg capsule, and expects to be entitled to 180 days of market exclusivity.

Once the ANDA is approved by FDA, Global Pharmaceuticals, Impax's generic division, will commercialize the products.

DEXILANT(R) is used to treat gastroesophageal reflux disease (GERD), a condition in which backward flow of acid from the stomach causes heartburn and possible injury of the esophagus (the tube between the throat and stomach). It is used to treat the symptoms of GERD, allow the esophagus to heal, and prevent further damage to the esophagus. DEXILANT(R) is in a class of medications called proton pump inhibitors. It works by decreasing the amount of acid made in the stomach. According to Wolters Kluwer Health, U.S. sales of DEXILANT(R) delayed-release capsules, 30 mg and 60 mg were approximately $20 million and $261 million, respectively, for the current 12 months ending January 2011.

[Bart Myers]

J.P. Morgan is out with its report today on Impax Laboratories (NASDAQ: IPXL), maintaining Overweight.

In a note to clients, J.P. Morgan writes, "With positive data in both advanced and naïve Parkinson's patients and 066 licensed to GSK outside of the US, Impax's investment in its branded business is beginning to show a return. We now see IPX 066 as a derisked asset that could have the potential to bring in more than $150 million in annual revenue with little further R&D outlay."


Source: http://www.benzinga.com/analyst-ratings/analyst-color/11/03/926828/j-p-morgan-maintains-overweight-on-impax-laboratories-ipx#ixzz1Gg6YisWk

[MrBruce]

Giddy up!!! +2.93/+13.28% in after hour trading!

March 14, 2011 04:01 PM Eastern Daylight Time

IPX066 Demonstrates Efficacy and Safety in ADVANCE-PD Phase III Study in Treatment of Advanced Parkinson’s Disease

IPX066 met the primary end point, significantly reducing percentage of “off time” over IR CD-LD

Conference call and Webcast presentation scheduled for Tuesday, March 15 at 9:00 a.m. ET


HAYWARD, Calif.--(BUSINESS WIRE)--Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced statistically significant, positive, top-line results of the ADVANCE-Parkinson’s Disease (PD) Phase III clinical study of the safety and efficacy of IPX066 versus immediate-release (IR) carbidopa-levodopa (CD-LD) in advanced PD patients experiencing motor fluctuations. IPX066 is an investigational extended release (ER) CD-LD product. The ADVANCE-PD results demonstrated that IPX066 produced significantly improved control of motor symptoms as compared to IR CD-LD in multiple clinical measures in subjects with advanced PD.

“In the ADVANCE-PD study, daily “off time”

The primary endpoint of this comparison study of IPX066 to IR CD-LD was the percentage of “off time” during waking hours. IPX066 demonstrated a 37% improvement from baseline for IPX066 vs. a 17% improvement from baseline for IR CD-LD (p<0.0001). “Off time” is the functional state when patients’ medication effect has worn off and there is a return of Parkinson’s symptoms.

The study enrolled 471 subjects on a stable regimen of IR CD-LD who were first entered into a dose-adjustment phase of their IR CD-LD, followed by a conversion to IPX066 after which they were then randomized to either IPX066 or IR CD-LD. Subjects converted to IPX066 experienced a reduction from baseline of more than 2 hours in total “off time” during waking hours, and this effect was maintained in the group then randomized to IPX066 during the blinded study portion. While the group treated with IR CD-LD achieved similar improvement during conversion to IPX066, “off time” worsened by 1.0 hours during double blind treatment with IR CD-LD (p<0.0001). In addition, during double-blind treatment, subjects experienced similar results in “on time” without troublesome dyskinesia with an increase of 1.9 hours for IPX066 compared to an increase of 0.8 hours for IR CD-LD as measured from study entry (p<0.001).

Additional clinical and patient-reported outcome measures in the study consistently demonstrate the improved IPX066 efficacy profile when compared to IR CD-LD. This includes the Unified Parkinson’s Disease Rating Scale (UPDRS), Clinician Global Impression of Change (CGI) and Patient Global Impression of Change (PGI), which also demonstrated significant improvements in treatment with IPX066 compared to IR CD-LD (p<0.0001 for all comparisons). In quality-of-life (QOL) measures, IPX066 demonstrated significant improvement over IR CD-LD as measured by PDQ-39 (p<0.035) and modified Rankin Test (p<0.006).

“Impax Pharmaceuticals is excited to report these positive results for the ADVANCE-PD trial demonstrating the clinical benefits of IPX066 over IR CD-LD, which is the gold standard in treating advanced PD,” stated Dr. Suneel Gupta, Impax Pharmaceuticals’ Chief Scientific Officer. “Consistent with our Phase II findings, these data show IPX066 provides a robust level of efficacy across a range of PD clinical and QOL measures, which represents a potentially significant improvement over existing treatment options. With the successful completion of this ADVANCE-PD trial and the APEX-PD trial in patients with early PD, we have completed the two required Phase III trials for a New Drug Application (NDA) as agreed with the Food and Drug Administration. We are working diligently to file an NDA in the fourth quarter of 2011."

IPX066 was generally well tolerated, and during the double-blind portion of the trial had an adverse event (AE) rate of 43% compared to 40% for IR CD-LD. The most common AEs reported for IPX066 included: insomnia, nausea, fall, dizziness, and dyskinesia (no event was associated with a greater than 3.5% overall incidence). The rate of related serious AEs was comparable, with one subject in each treatment arm reporting serious treatment-related AEs in the double-blind treatment phase.

According to Robert A. Hauser, MD, Professor of Neurology, Molecular Pharmacology, and Physiology and Director of the Parkinson's Disease & Movement Disorders Center at the University of South Florida and an ADVANCE-PD study investigator, “There is a major unmet need in patients with advanced PD for a therapy that can consistently extend and improve motor symptom control through the day and enhance quality of life.” Dr. Hauser added, “In the ADVANCE-PD study, daily “off time” was reduced without worsening of dyskinesia, and both patients and clinicians reported overall improvement. The magnitude of benefit observed with IPX066 was clinically significant and results indicate that PD patients should be able to enjoy improved control of their motor symptoms and a better quality of life.”

Impax Pharmaceuticals plans to present complete results of the ADVANCE-PD study at an upcoming scientific meeting.

Conference Call Information

The Company will host a conference call and Webcast with a slide presentation on Tuesday, March 15 at 9:00 a.m. ET to discuss the results. The number to call from within the United States is [phone] and [phone] internationally. The call can also be accessed via a live Webcast through the Investor Relations section of the Company’s Web site, www.impaxlabs.com. In addition, a copy of the slide presentation is available in the Investor Relations section. A replay of the conference call will be available shortly after the call for a period of seven days. To access the replay, dial [phone] (in the U.S.) and [phone] (international callers). The access conference code is 8896538.

About Our Collaboration with GlaxoSmithKline (GSK)

Impax Pharmaceuticals and GSK announced an agreement for the development and commercialization of IPX066, outside the United States and Taiwan, in December 2010. Under the terms of the agreement, GSK received an exclusive license to sell IPX066 throughout the world except in the U.S. and Taiwan. Impax will complete the current Phase III program for IPX066, which includes the ADVANCE-PD study.

About the ADVANCE-PD Study and IPX066 Development Program

The ADVANCE-PD study is the second of two pivotal trials designed to support an NDA for IPX066 in PD. The study is a randomized, double-blind, active-control, parallel-group Phase III study of the safety and efficacy of IPX066 versus IR CD-LD in advanced PD patients with motor fluctuations. The trial enrolled 471 subjects in North America and Europe of which 393 subjects were randomized to participate in the 13-week comparison of IPX066 versus IR CD-LD. Prior to randomization, subjects on a stable IR CD-LD dose regimen entered a 3-week dose-adjustment or dose optimization period for IR CD-LD, followed by a 6-week dose-conversion period to IPX066. Subjects were instructed to take IPX066 three times a day.

The ADVANCE-PD trial results complement the earlier announced positive APEX-PD Phase III study in early PD. APEX-PD was a randomized, double-blind, placebo-controlled, parallel group, fixed-dose study comparing 3 doses of IPX066 to placebo in 381 patients with early PD.

The Company is also conducting the ASCEND-PD comparative study of IPX066 and carbidopa-levodopa and entacapone, which is currently enrolling subjects.

An Open Label Extension study for subjects from the ADVANCE-PD and APEX-PD studies is also ongoing.

About IPX066

IPX066 is an investigational CD-LD product with an enhanced pharmacokinetic profile. The IPX066 pharmacokinetic profile has the potential to offer reliable control of PD symptoms, such as the reduction in “off time” throughout the day, which has been observed in preliminary studies of IPX066.

About Parkinson’s Disease

Parkinson’s Disease is a chronic neurodegenerative movement disorder affecting over three million people in the US, Europe, and Japan.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. is a technology-based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax has developed marketing partnerships to fully leverage its technology platform. Impax is headquartered in Hayward, California, and has a full range of capabilities in its Hayward, Philadelphia and Taiwan facilities. For more information, please visit the Company's Web site at: www.impaxlabs.com.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

To the extent any statements made in this news release contain information that is not historical, these statements are forward-looking in nature and express the beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause the Company’s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the effect of current economic conditions on the Company’s industry, business, financial position and results of operations, the ability to maintain an effective system of internal control over financial reporting, fluctuations in revenues and operating income, the ability to successfully develop and commercialize pharmaceutical products, reductions or loss of business with any significant customer, the impact of competition, the ability to sustain profitability and positive cash flows, any delays or unanticipated expenses in connection with the operation of the Taiwan facility, the effect of foreign economic, political, legal and other risks on operations abroad, the uncertainty of patent litigation, consumer acceptance and demand for new pharmaceutical products, the difficulty of predicting Food and Drug Administration filings and approvals, the inexperience of the Company in conducting clinical trials and submitting new drug applications, the ability to successfully conduct clinical trials, reliance on alliance and collaboration agreements, the availability of raw materials, the ability to comply with legal and regulatory requirements governing the healthcare industry, the regulatory environment, the ability to protect the Company’s intellectual property, exposure to product liability claims and other risks described in the Company’s periodic reports filed with the Securities and Exchange Commission. Forward-looking statements speak only as to the date on which they are made, and Impax undertakes no obligation to update publicly or revise any forward-looking statement, regardless of whether new information becomes available, future developments occur or otherwise.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6646211&lang=en
Contacts

Impax Laboratories, Inc.
Mark Donohue
Sr. Director
Investor Relations and Corporate Communications
215-558-4526
www.impaxlabs.com

[StocksDiva]

IPXL Receives Final FDA Approval for Generic Doryx® 75 and 100mg Tablets

http://www.businesswire.com/news/home/20101229005408/en

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company’s Abbreviated New Drug Application for the generic version of Doryx® (doxycyline hyclate delayed-release) 75 and 100mg tablets. The Company is preparing for product launch through Global Pharmaceuticals, Impax’s generic division.

In December 2008, Warner Chilcott Limited and Mayne Pharma International Pty. Ltd. filed suit against the Company in the U.S. District Court for the District of New Jersey, alleging patent infringement for the filing of the Company’s ANDA. Litigation is ongoing.

Doryx® is a tetracycline-class antibacterial indicated for rickettsial infections, sexually transmitted infections, respiratory tract infections, specific bacterial infections, ophthalmic infections, anthrax, including inhalational anthrax (post-exposure), alternative treatment for selected infections when penicillin is contraindicated, adjunctive therapy in acute intestinal amebiasis and severe acne, and prophylaxis of malaria. According to Wolters Kluwer Health, U.S. sales of Doryx® 75 and 100 mg were approximately $25 million in the 12 months ended October 2010.

[dickmilde]

Neil_B Opening price...

It's hard to tell with the strong results and market futures in the toilet. Right now IPXL is up 10.0% but that may not hold given the overall weakness. It was up almost 20% earlier this morning so we may have already seen the high. For now, I am still holding my overweight position.

Dick Milde

[dickmilde]

IPXL Impax Laboratories Reports Significant Growth for the First Quarter 2010

First-Quarter Highlights (versus the prior year period)

The Company set multiple Financial Records in the First-Quarter

* Record total revenue of $323.3 million – up $264.4 million
* Generic Flomax® launched on March 2 added $176.2 million of revenue and $167.9 million of gross profit
* Record total gross profit of $243.8 million – up $211.1 million
* Gross profit margin increased to 75.4% - up from 55.4%
* Record income from operations of $211.0 million - up $206.8 million
* Record net income of $131.5 million – up $129.3 million
* Record earnings per diluted share of $2.06 – up $2.02

The earnings estimate was .49 for the quarter!

Dick Milde

[dickmilde]

This stock looks like a bargain...

The earnings estimate was just raised for Q1. In the last 90 days the estimate has DOUBLED.

The PE using the year end estimate is 13.4.

The sales growth is forecast to be 171%.

What am I missing?

Here is a current company presentation:

http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MzcxOTJ8Q2hpbGRJRD0tMXxUeXBlPTM=&t=1

I doubled my position last week, I hope I'm not disapointed!

Dick Milde

[fink]

No post need a tag to my name

[TycoonSoon]

IPXL news: FDA Approval...

Impax Laboratories Receives Final FDA Approval for Generic Depakote® Extended-Release 500mg Tablets

* Press Release
* Source: Impax Laboratories, Inc.
* On Wednesday August 5, 2009, 1:00 pm EDT

HAYWARD, Calif.--(BUSINESS WIRE)--Impax Laboratories, Inc. (NASDAQ:IPXL - News) today confirmed that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company’s Abbreviated New Drug Application (ANDA) for generic version of Depakote® (divalproex ER) 500mg Extended-release Tablets. The Company received approval on the 250mg tablets in May 2009. Abbott Laboratories markets Depakote® ER for the treatment of epilepsy and bipolar disorders.

The Company expects to launch both the 250mg and 500mg tablets immediately, through Global Pharmaceuticals, Impax’s generic division.

According to Wolters Kluwer Health, U.S. sales of Depakote® ER 250mg and 500mg tablets were approximately $93 million and $633 million, respectively, for the 12 months ended June 30, 2009.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax has developed marketing partnerships to fully leverage its technology platform. Impax Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward and Philadelphia facilities. For more information, please visit the Company's Web site at: www.impaxlabs.com.

[trendseeker]

Formed what appears to be a continuation triangle. Looks like it's likely to go higer to me.

[PatD100]

Impax Receives Final FDA Approval for Generic Depakote(R) Extended-Release 250mg Tablets
5:46p ET May 6, 2009 (Business Wire)
Impax Laboratories, Inc. (NASDAQ: IPXL) today confirmed that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company's Abbreviated New Drug Application (ANDA) for generic version of Depakote(R) (divalproex ER) 250mg Extended-release Tablets. The Company also received tentative approval on the 500mg tablets and expects to receive final approval on August 3, 2009, upon expiration of the 180-day exclusivity period. Abbott Laboratories markets Depakote(R) ER for the treatment of epilepsy and bipolar disorders.

The Company expects to launch both the 250mg and 500mg tablets on August 3, 2009, through Global Pharmaceuticals, Impax's generic division.

According to Wolters Kluwer Health, U.S. sales of Depakote(R) ER 250mg and 500mg tablets were approximately $115 million and $796 million, respectively, for the 12 months ended March 2009.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax has developed marketing partnerships to fully leverage its technology platform. Impax Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward and Philadelphia facilities. For more information, please visit the Company's Web site at: www.impaxlabs.com.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

To the extent any statements made in this news release contain information that is not historical, these statements are forward-looking in nature and express the beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause Impax's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to; ability to timely file periodic reports required by the Exchange Act; ability to maintain an effective system of internal control over financial reporting; ability to sustain profitability and positive cash flows; ability to maintain sufficient capital to fund operations; any delays or unanticipated expenses in connection with the construction of our Taiwan facility; ability to successfully develop and commercialize pharmaceutical products; the uncertainty of patent litigation; consumer acceptance and demand for new pharmaceutical products; the impact of competitive products and pricing; the difficulty of predicting Food and Drug Administration ("FDA") filings and approvals; inexperience in conducting clinical trials and submitting new drug applications; reliance on key alliance agreements; the availability of raw materials; the regulatory environment; exposure to product liability claims; fluctuations in operating results and other risks detailed from time to time in our filings with the Securities and Exchange Commission. Forward-looking statements speak only as to the date on which they are made, and Impax undertakes no obligation to update publicly or revise any forward-looking statement, regardless of whether new information becomes available, future developments occur or otherwise.

SOURCE: Impax Laboratories, Inc.

Impax Laboratories, Inc. Mark Donohue, 215-933-3526 Sr. Director Investor Relations www.impaxlabs.com

[PatD100]

FDA Approval News released after hours TODAY!